Breast Cancer: Triple - Negative: Epidemiology and Patient-Based Market Forecasts - Which Branded Therapies Will Have the Largest Commercial Potential in the Triple-negative Breast Cancer Market? - Research and Markets
The aggressive nature of triple-negative breast cancer and a lack of targeted therapies creates opportunities for pipeline candidates to fulfil areas of high unmet need.
This report addresses the following questions:
- Which branded therapies will have the largest commercial potential in the triple-negative breast cancer market? - What impact will immunotherapies have on treatment algorithms in triple-negative breast cancer? - How will competing poly (ADP-ribose)polymerase (PARP) inhibitors Lynparza, niraparib, talazoparib, and veliparib fare against one another? - How will pipeline therapies aim to address areas of unmet need? - When will generic and biosimilar therapies enter the market and what impact will they have on revenues?
- Executive Summary - Disease Definition and Diagnosis - Primary Research Methodology - Patient Segmentation - Country Treatment Trees - Current Treatment Options - Prescribing Trends - Unmet Needs in Triple-Negative Breast Cancer
EPIDEMIOLOGY: TRIPLE-NEGATIVE BREAST CANCER
- Executive Summary - Disease Background - Sources and Methodology - Forecast - Epidemiologist Insight - Strengths and Limitations